NCT06723691已完成1 期
A Single Center, Open-label, Two Cohorts, Fixed Sequence Trial, Investigating the Influence of HRS9531 Injection on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 57
- 试验地点
- 1
- 主要终点
- Area under the acetaminophen plasma concentration-time curve
研究概览
简要总结
The purpose of this study is to evaluate the influence of HRS9531 injection on gastric emptying and pharmacokinetics of metformin, atorvastatin, warfarin, and digoxin in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Ability to understand the trial procedures and possible adverse events, be able and willing to provide a written informed consent;
- •Male subjects aged 18-45 years on the date of signing informed consent (inclusive);
- •Body weight ≥60 kg, body mass index (BMI) within the range of 24.0-35.0 kg/m2 (inclusive);
- •HbA1c<6.0%;
- •The subjects have no plans to have children and voluntarily take effective contraceptive measures from the time of signing the informed consent to 2 months after the last medication, and have no plans to donate eggs/sperm; the pregnancy test of female subjects with fertility must be negative.
排除标准
- •Chronic or severe medical history of the respiratory system, circulatory system, digestive system, urinary system, blood system, endocrine system, immune system, nervous system, mental system, etc., or those with existing systemic diseases mentioned above, and judged by the investigator to be unsuitable to participate in this study;
- •Past history or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2), a history of pancreatitis or symptomatic gallbladder stones;
- •History of disease that increases the risk of bleeding;
- •Surgery within 6 months prior to dosing, planned to undergo surgery during the study period;
- •Participation in clinical trials of any drug or medical device in the 3 months or 5 half-lives, whichever longer, prior to dosing;
- •Blood donation history or blood loss ≥400 mL within 3 months or ≥200 mL within 1 month before dosing, or received blood transfusion within 3 months before dosing;
- •Hepatitis B surface antigen (HBsAg), HIV antibody, hepatitis C virus antibody (HCVAb), treponema pallidum specific antibody detection, positive;
- •Abnormal laboratory test results or abnormal examinations considered unsuitable to participate in this trial;
- •History of hypoglycaemia;
- •History of syncope or vasovagal episodes, difficulty with blood collection, or an inability to tolerate venipuncture;
- •The investigator considers that the subject has any other factors that would make it inappropriate to participate in this study.
研究组 & 干预措施
Treatment group
Experimental
干预措施: Digoxin (Drug)
Treatment group
Experimental
干预措施: HRS9531 (Drug)
Treatment group
Experimental
干预措施: Atorvastatin (Drug)
Treatment group
Experimental
干预措施: Acetaminophen (Drug)
Treatment group
Experimental
干预措施: Metformin (Drug)
Treatment group
Experimental
干预措施: Warfarin (Drug)
结局指标
主要结局
Area under the acetaminophen plasma concentration-time curve
时间窗: From time 0 to 24 hours after a single dose.
Maximum observed acetaminophen concentration
时间窗: From time 0 to 24 hours after a single dose.
Time of maximum observed acetaminophen concentration
时间窗: From time 0 to 24 hours after a single dose.
Area under the metformin plasma concentration-time curve
时间窗: From time 0 to 12 hours after the last of 7 repeated doses.
Area under the S-warfarin plasma concentration-time curve
时间窗: From time 0 to 168 hours after a single dose.
Area under the atorvastatin plasma concentration-time curve
时间窗: From time 0 to 72 hours after a single dose.
Area under the digoxin plasma concentration-time curve
时间窗: From time 0 to 120 hours after a single dose.
次要结局
- Area under the concentration versus time curve of acetaminophen from 0 to infinity(Start of treatment up to 168 hours.)
- Apparent volume of distribution of acetaminophen(Start of treatment up to 168 hours.)
- Time of maximum observed metformin concentration after 3.5 days of treatment(Start of Treatment up to 30 hours.)
- Clearance of metformin after 3.5 days of treatment(Start of Treatment up to 30 hours.)
- Apparent volume of distribution of metformin after 3.5 days of treatment(Start of Treatment up to 30 hours.)
- Time of maximum observed S-warfarin concentration(Start of Treatment up to 168 hours.)
- Clearance of S-warfarin(Start of Treatment up to 168 hours.)
- Apparent volume of distribution of S-warfarin(Start of Treatment up to 168 hours.)
- Time of maximum observed atorvastatin (and its active metabolites) concentration(Start of Treatment up to 72 hours.)
- Clearance of atorvastatin (and its active metabolites)(Start of Treatment up to 72 hours.)
- Time of maximum observed digoxin concentration(Start of Treatment up to 120 hours.)
- Maximum observed digoxin concentration(Start of Treatment up to 120 hours.)
- Clearance of digoxin(Start of Treatment up to 120 hours.)
- Apparent volume of distribution of digoxin(Start of Treatment up to 120 hours.)
- Time of maximum observed HRS9532 concentration(Start of Treatment up to 168 hours.)
- Maximum observed HRS9531 concentration(Start of Treatment up to 168 hours.)
- Area under the concentration versus time curve of HRS9531 from 0 to the time of the last measurable (positive) concentration(Start of Treatment up to 168 hours.)
- Area under the concentration versus time curve of HRS9531 from 0 to infinity(Start of Treatment up to 168 hours.)
- Incidence and severity of adverse events(Screening period up to 117 days.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy SubjectsType 2 DiabetesNCT06654960Fujian Shengdi Pharmaceutical Co., Ltd.20
已完成
2 期
Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic GastroparesisDiabetes Mellitus ComplicationsDiabetes MellitusGastroparesisNCT01571297Motus Therapeutics, Inc.204
尚未招募
2 期
A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep ApneaWeight ManagementNCT06565871Fujian Shengdi Pharmaceutical Co., Ltd.108
已完成
不适用
Effect of Ramosetron on the rate of gastric emptyingJPRN-UMIN000007930Gastroenterology Division, Yokohama City University Graduate School of Medicine10
已完成
1 期
Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal FunctionContrast-Enhanced Magnetic Resonance Imaging DetectionNCT06657560Shanghai Shengdi Pharmaceutical Co., Ltd41